Join Dr. Ethan Shelkey as he discusses human primary co-culture models with immune cells that are used in infectious disease studies and cancer therapeutic testing.

With the implementation of the FDA Modernization Act, which encourages the use of human primary cell systems in place of traditional animal models, there is a growing emphasis on the development and application of advanced in vitro coculture models. This webinar will explore the critical role of co-culture systems incorporating immune cells in enhancing the physiological relevance and predictive power of preclinical studies.

We will delve into key applications of co-culture models, focusing on lung epithelial cell and PBMC-based systems for infectious disease research, including their use in simulating human immune responses to viral and bacterial infections. The session will also highlight the utility of co-culture models in cancer therapeutic testing, including antibody-dependent cellular cytotoxicity (ADCC) assays using cancer cell–PBMC systems, T-cell and dendritic cell (T:DC) interactions, and evaluations of off-target immune toxicity.

Attendees will gain insight into how these human cell-based models provide a more accurate representation of in vivo biology, and accelerate the development of safer, more effective therapies. This session is ideal for researchers, pharmacologists, and regulatory professionals aiming to modernize their in vitro testing strategies in alignment with emerging scientific and policy framework.

Key Topics Include:

  • Key aspects of the FDA modernization act
  • Modeling lung inflammation using a bronchial epithelial and immune PBMC coculture
  • Immune cell models for cancer therapeutic testing and off target toxicity testing

Presenters

Research Scientist
Lonza

Ethan Shelkey, Ph.D. is a Research Scientist with the Bioscience Division at Lonza. As part of the team at the primary human cell isolation site, Ethan works to develop new assays for cell use and new protocols for improved cell characterization. He is the technical subject matter expert many of the projects involving immunology or genomics. Previous to his role at Lonza, he worked to create immune-competent 3D models of patient tumours to test immunotherapy efficacy.

Production Partner

Lonza Bioscience

Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our colleagues work alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

Additional Content From Lonza Bioscience

Additional Content From Scientist.com

Related Content